The F(ab)-fragment of a PAI-1 inhibiting antibody reduces thrombus size and restores blood flow in a rat model of arterial thrombosis

Thrombosis and Haemostasis

Volumn 77, Issue 5, 1997, Pages 964-969

  Van Giezen, J J J ^a   Wahlund, G ^a   Nerme, V ^a   Abrahamsson, T ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

FERRIC CHLORIDE; HEPARIN; IMMUNOGLOBULIN F(AB) FRAGMENT; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYCLONAL ANTIBODY; TISSUE PLASMINOGEN ACTIVATOR; TRANEXAMIC ACID; ANTIFIBRINOLYTIC AGENT; FERRIC ION;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY BLOOD FLOW; ARTERY THROMBOSIS; ARTICLE; CAROTID ARTERY; CONTROLLED STUDY; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; THROMBUS; TISSUE PERFUSION; ANIMAL; BLOOD FLOW VELOCITY; CAROTID ARTERY THROMBOSIS; DRUG ADMINISTRATION; DRUG EFFECT; IMMUNOLOGY; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT; TIME;

ANIMALS; ANTIFIBRINOLYTIC AGENTS; BLOOD FLOW VELOCITY; CAROTID ARTERIES; CAROTID ARTERY THROMBOSIS; DRUG ADMINISTRATION SCHEDULE; FERRIC COMPOUNDS; IMMUNOGLOBULIN FAB FRAGMENTS; PLASMINOGEN ACTIVATOR INHIBITOR 1; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TRANEXAMIC ACID;

EID: 0030610091     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1656086     Document Type: Article

References (34)

1. Krishnamurti C, Alving BM. Plasminogen activator inhibitor type 1: Biochemistry and evidence for modulation of fibrinolysis in vivo. Sem Thromb Hemost 1992; 18: 67-80.
2. Schneiderman J, Loskutoff DJ. Plasminogen activator inhibitors. Trends in Cardiovasc Med 1991; 1: 99-102.
3. Padro T, Quax PHA, van den Hoogen CM, Roholl P, Verheijen JH, Emeis JJ. Tissue-type plasminogen activator and its inhibitor in rat aorta: effect of endotoxin. Arterioscler Thromb 1994; 14: 1459-65.
4. Booth NA, Simpson AJ, Croll A, Bennett B, MacGregor IR. Plasminogen activator inhibitor (PAI-1) in plasma and platelets. Brit J Haematol 1988; 70: 327-33.
5. Rocha E, Páramo JA. The relationship between impaired fibrinolysis and coronary heart disease: a role for PAI-1 (review). Fibrinolysis 1994; 8: 294-303.
6. Schleef RR, Higgins DL, Pillemer E, Levitt LJ. Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor. J Clin Invest 1989; 83: 1747-52.
7. Dieval J, Nguyen G, Gross S, Delobel J, Kruithof DJ. A lifelong bleeding disorder associated with a deficiency of plasminogen activator inhibitor type 1. Blood 1991; 77: 528-32.
8. Fay WP, Shapiro AD, Shih JL, Schleef RR, Ginsburg D. Brief report: Complete deficiency of plasminogen-activator inhibitor type 1 due to a frameshift mutation. N Engl J Med 1992; 327: 1729-33.
9. Potter van Loon BJ, Rijken DC, Brommer EJP, van der Maas APC. The amount of plasminogen, tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in human thrombi and the relation to ex-vivo lysability. Thromb Haemost 1992; 67: 101-5.
10. Stringer HAR, van Swieten P, Heijnen HFG, Sixma JJ, Pannekoek H. Plasminogen activator inhibitor-1 released from activated platelets plays a key role in thrombolysis resistance. Studies with thrombi generated in the Chandler loop. Arterioscler Thromb 1994; 14: 1452-8.
11. Keijer J, Linders M, van Zonneveld A-J, Ehrlich HJ, de Boer J-P, Pannekoek H. The interaction of plasminogen activator inhibitor 1 with plasminogen activators (tissue-type and urokinase-type) and fibrin: localisation of interaction sites and physiologic relevance. Blood 1991; 78: 401-9.
12. Hladovec J. Experimental arterial thrombosis in rats with continuous registration. Thromb Diath Haemorrh 1973; 29: 407-10.
13. Kurz KD, Main BW, Sandusky E. Rat model of arterial thrombosis induced by ferric chloride. Thromb Res 1990; 60: 269-80.
14. Kawasaki T, Kawamura S, Katoh S, Takenaka T. Experimental model of carotid artery thrombosis in rats and the thrombolytic activity of YM866, a novel modified tissue-type plasminogen activator. Japan J Pharmacol 1993; 63: 135-42.
15. Abrahamsson T, Björquist, Deinum J, Ehnebom J, Hulander M, Legnehed A, Matsson C, Nerme V, Westin-Eriksson A, Åkerblom B. An antibody fragment against PAI-1 inhibits PAI-1 activity and stimulates fibrinolysis in vitro and in vivo. Fibrinolysis 1994; 8 (suppl. 2): 55-6.
16. Abrahamsson T, Nerme V, Strömqvist M, Åkerblom B, Legnehed A, Pettersson, Westin Eriksson A. Anti-thrombotic effect of a PAI-1 inhibitor in rats given endotoxin. Thromb Haemost 1996; 75: 118-26.
17. Green CJ. Animal anaesthesia. Laboratory animals Ltd. London 1979.
18. Longstaff C. Studies on the mechanisms of action of aprotinin and tranexamic acid as plasmin inhibitors and anti fibrinolytic agents. Blood Coag Fibrinol 1994; 5: 537-42.
19. Bode C, Nordt TK, Runge MS. Thrombolytic therapy in acute myocardial infarction - selected recent developments. Ann Hematol 1994; 69: S35-S40.
20. Lenfors S, Marberg L, Wikström S, Johnsson U, Westin Eriksson A, Gustafsson D. A new rat model of arterial thrombosis with a platelet-rich head and a erythrocyt-rich tail: thrombolysis experiments with specific thrombin inhibition. Blood Coag Fibrinol 1993; 4: 263-71.
21. Clemensen I. Three new E-antigenic fibrinogen fractions found in an commercial plasmin preparation. Science Tools. LBK Intr J 1973; 20: 7-8.
22. Bukh A, Ingerslev J, Stenbjerg S. Møller NPH. The multimeric structure of plasma FVIII:RAg studied by electroelution and immunoperoxidase detection. Thromb Res 1986; 43: 579-84.
23. Wiman B, Mellbring G, Rånby M. Plasminogen activator release during venous stasis and exercise as determined by a new specific assay. Clin Chim Acta 1983; 127: 279-88.
24. Gast A, Tschopp TB, Schmid G, Hilpert K, Ackermann J. Inhibition of clotbound and free (fluid-phase thrombin) by a novel synthetic thrombin inhibitor (Ro 46-6240), recombinant hirudin and heparin in human plasma. Blood Coag Fibrinol 1994; 5: 879-87.
25. Páramo JA, Colluci M, Collen D, van der Werf F. Plasminogen activator inhibitor in the blood of patients with coronary artery disease. Br Med J 1985; 291: 573-4.
26. Levi M, Biemond B, van Zonneveld A-J, ten Cate JW, Pannekoek H. Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis. Circulation 1992; 85: 305-12.
27. Biemond BJ, Levi M, Coronel R, Janse MJ, ten Cate JW, Pannekoek H. Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis: effects of a plasminogen activator inhibitor type 1 neutralizing monoclonal antibody. Circulation 1995; 91: 1175-81.
28. Eitzman DT, Fay WP, Lawrence DA, Francis-Chmura AM, Shore JD, Olson ST, Ginsburg D. Peptide-mediated inactivation of recombinant and platelet plasminogen activator inhibitor-1 in vitro. J Clin Invest 1995; 95: 2416-20.
29. Podor TJ, Hirsh J, Gelehrter TD, Zeheb R, Torry D, Guigoz Y, Sierra F, Gauldie J. Type 1 plasminogen activator inhibitor is not an acute phase reactant in rats. Lack of IL-6-and hepatocyte-dependent synthesis. J Immunol 1993; 150: 225-35.
30. Robbie LA, Booth NA, Young S, Bennett B. A study of thrombi formed in the Chandler loop. Thromb Haemost 1995; 73: 1005 (abstract).
31. Mimuro J, Schleef RR, Loskutoff DJ. Extracellular matrix of cultured bovine aortic endothelial cells contains functionally active type 1 plasminogen activator inhibitor. Blood 1987; 70: 721-8.
32. Fay WP, Murphy JG, Owen WG. High concentrations of active plasminogen activator inhibitor-1 in porcine coronary artery thrombi. Arterioscler Thromb Vasc Biol 1996; 16: 1277-84.
33. Fay WP, Eitzman DT, Shapiro AD, Madison EL, Ginsberg D. Platelets inhibit fibrinolysis in vitro by both plasminogen activator inhibitor-1-dependent and -independent mechanisms. Blood 1994; 83: 351-6.
34. Gustafsson D, Elg M, Lenfors S, Börjesson I, Teger-Nilsson A-C. Effects of inogatran, a low-molecular-weight thrombin inhibitor, in rat models of venous and arterial thrombosis, thrombolysis and bleeding time. Blood Coag Fibrinol 1996; 7: 69-79.